Covid-19: Evaluation of the Immunogenicity, Safety, and Tolerability of a Single Dose of ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2: a Phase 3 Trial in Two Parts—Randomized, Double-blind, Active Controlled and Open-label, Single-arm

Bavarian Nordic A/S0 个研究点目标入组 4,000 人开始时间: 2022年8月18日最近更新: 2023年10月23日

适应症

试验速览

阶段: 1 期
状态: 进行中（未招募）
发起方: Bavarian Nordic A/S
入组人数: 4,000

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

性别: All

入选标准

•1. Age =18 years at screening.
•2. Documented, previous completion of a primary vaccination regimen
•with locally authorized SARS-CoV-2 vaccine(s) or completion of primary
•plus 1 boost vaccination (see definition of completed primary vaccination
•regimen and completed primary plus boost vaccination in Section 1.2),
•with last vaccination at least 3 months before screening. Locally
•authorized” SARS-CoV-2 vaccines are those that have received market
•approval or emergency use authorization in the country of enrollment
•3. Absence of acute medical illness, significant physical exam findings, or laboratory abnormalities, as determined by the investigator.
•4. Informed consent, provided by the subject prior to performance of any trial-specific procedures; the subject has read, signed, and dated an informed consent form (ICF), having been advised of the risks and benefits of the trial in a language understood by the subject.
•5. Body mass index (BMI) =18.5 and <40.
•6. For female subjects of childbearing potential (WOCBP) and male subjects who are sexually active with a WOCBP, agreement to use an effective method of birth control from at least 30 days prior to administration of the vaccine until 30 days after the vaccination. A woman is considered of childbearing potential unless post-menopausal (defined as =12 months without a menstrual period at screening) or surgically sterilized (bilateral oophorectomy, bilateral tubal ligation, hysterectomy). Acceptable contraception methods are restricted to abstinence (only acceptable if refraining from heterosexual intercourse during the period of 30 days prior to administration of the vaccine until 30 days after the vaccination), double barrier contraceptives, vasectomy, intrauterine contraceptive devices, or licensed hormonal products.
•7. For WOCBP, a negative serum pregnancy test at screening.
•8. Negative tests for human immunodeficiency virus antibody (anti-HIV), hepatitis B surface antigen (HBsAG), and antibody to hepatitis C virus (HCV).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 3000
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 1000

排除标准

•1. History of COVID-19 infection within the last 3 months before screening.
•2. Previous vaccination with a SARS-CoV-2 vaccine other than those mentioned in inclusion criterion #2.
•3. Positive test for SARS-CoV-2 infection at screening.
•4. Breastfeeding with intent to continue.
•5. Acute or chronic medical condition that, in the opinion of the investigator, would render the trial procedures unsafe or would interfere with the evaluation of the responses.
•6. History of myocarditis or pericarditis.
•7. History of or active autoimmune disease. History of Guillain-Barré syndrome or Reye’s syndrome. Persons with vitiligo or thyroid disease taking thyroid replacement are not excluded.
•8. Known or suspected impairment of immunologic functions including, but not limited to, known immunodeficiency syndrome.
•9. History of malignancy other than squamous cell or basal cell skin cancer, unless there has been surgical excision at least 6 months prior to screening that is considered to have achieved cure. Subjects with history of skin cancer must not be vaccinated at the previous tumor site.
•10. Laboratory parameters (such as complete blood count, serum biochemistry including aspartate aminotransferase [AST], alanine amino transferase [ALT], alkaline phosphokinase [ALP], bilirubin, or creatinine values), pulse rate, or blood pressure, or electrocardiogram (ECG) outside normal range at screening and deemed clinically relevant by the investigator.
•11. Clinically significant mental disorder not adequately controlled by medical treatment.
•12. Active or recent history (within 6 months before screening) of chronic alcohol abuse, or illicit drug abuse.
•13. History of allergic disease or reactions likely to be exacerbated by any component of the vaccine.
•14. History of anaphylaxis or severe allergic reaction to any vaccine.
•15. History of any vaccinations or plan to receive any vaccinations with a live vaccine within 30 days prior to or after trial vaccination.
•16. History of any vaccinations or plan to receive any vaccinations with a non-live vaccine within 14 days prior to or after trial vaccination.
•17. Recent blood donation (including platelets, plasma and red blood cells) within 4 weeks prior to screening, or planned blood donations during the active phase of the trial.
•18. Chronic systemic administration (defined as more than 14 days) of >5 mg prednisone (or equivalent)/day, or any other immune-modifying drugs during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after vaccination. The use of topical, inhaled, ophthalmic and nasal glucocorticoids is allowed.
•19. History of organ transplantation, whether or not accompanied by chronic immunosuppressive therapy.
•20. Administration or planned administration of immunoglobulins and/or any blood products during a period starting 3 months prior to administration of the vaccine and ending 4 weeks after vaccination. Receipt of packed red blood cells given for an emergency indication in an otherwise healthy person, and not required as ongoing treatment is not exclusionary (for example packed red blood cells given in emergency during an elective surgery).
•21. Use of any investigational or non-registered drug or vaccine other than the trial vaccine within 30 days preceding the administration of trial vaccine, or planned administration of such a drug or vaccine throughout the trial.
•22. Involvement in this trial as site personnel.
•23. Known bleeding disorder that, in the opinion of

研究者

发起方

Bavarian Nordic A/S

相似试验

招募中

2 期

Immunogenicity and the safety of the COVID-19 vaccines available in Thailand.The immune response after COVID-19 vaccine administration in healthy volunteers.COVID-19 vaccine, Sputnik V, ChAdOx1, coronavac, Sinovac.

TCTR20210517006Chulabhorn Royal Academy3,000

招募中

不适用

Evaluation of the immune response against COVID-19 in pediatric Cancer patients after vaccinatioeed for vaccination against COVID-19C91C92Lymphoid leukaemiaMyeloid leukaemia

DRKS00025254Pädiatrische Hämatologie und OnkologieKlinik für Kinder- und JugendmedizinJohann Wolfgang Goethe Universität100

已完成

4 期

The immune-response and safety of COVID-19 vaccination in patients with chronic kidney disease, on dialysis, or living with a kidney transplant

NL-OMON51071niversitair Medisch Centrum Groningen850

进行中（未招募）

1 期

EUCTR2021-000868-30-NLRECOVAC consortium850

尚未招募

4 期

Assessment of the protection offered by single dose of COVID-19 vaccines in individuals previously affected with COVID-19

CTRI/2021/10/037099Indian Council of Medical research ICMR